OPTISCAN IMAGING LIMITED (OIL)

The suspension of trading in the securities of Optiscan Imaging Limited will be lifted immediately following the release by OIL of an announcement.

Carl Zeiss Meditec AG has informed Optiscan Imaging Limited that it has achieved another milestone on its regulatory pathway with FDA clearance and is progressing as planned with full commercialization of CONVIVO. At this time, there is no change to the forecast revenue from CZM of A$1.5m for the financial year ending 30 June 2019 which was provided in the Directors Report forming part of the Optiscan 2018 Annual Report.

The securities of Optiscan Imaging Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of OIL, pending the release of an announcement regarding a regulatory approval.

The securities of Optiscan Imaging Limited will be reinstated to quotation at the commencement of trading on Monday, 22 August 2016, following the release of an announcement by the Company in relation to a rights issue.

Optiscan Limited advises that shares have been issued to shareholders under the 2 for 9 pro-rata rights issue. A total of 22,078,044 new OIL shares have been issued to 400 shareholders.

The underwritten non-renounceable pro-rata Rights Issue of two (2) new share for every nine (9) shares held on the Record Date at an issue price of 2.5 cents ($0.025) per share to raise $1,415,777 before costs of the issue closed on 12 August 2016. Optiscan received valid acceptances from shareholders for 22,078,044 shares ($551,951.10). The total shortfall under the Rights Issue was 34,546,874 shares.

Optiscan advises the despatch on 3 August 2016 of the Prospectus and Supplementary Prospectus for the Company's 2 for 9 Non-Renounceable Rights Issue, as lodged on 25 and 29 July 2016 respectively with ASIC and ASX. This includes the Entitlement and Acceptance Application form.

The company issues a Supplementary Prospectus to supplement the Prospectus dated 22 July 2016 (Prospectus) issued by Optiscan Imaging Limited.

The company releases a rights issue letter to ineligible shareholders.

The company releases a rights issue letter to eligible shareholders.

Letters to optionholders were sent.

The company releases a letter from the chairman regarding the rights issue.

The company issues a prospectus for a non-renounceable pro rata Rights Issue of 2 new shares for every 9 Shares held on the Record Date at an issue price of 2.5 cents ($0.025) per New Share issued to raise up to approximately $1,415,000 before costs of the issue. The Rights Issue is underwritten by Life Sciences. The Rights Issue closes at 5pm (Melbourne time) on 12 August 2016 (which date may change without notice).

Optiscan Imaging Limited is delighted to announce its intention to convert a director's loan to equity. Mr Ian Mann is a Non-Executive Director of Optiscan. As previously communicated, entities associated with Mr Mann have made loans to the Company totalling $600,000. Subject to shareholder approval, the Company will issue 24,000,000 Optiscan shares to the lending parties. It is proposed that the conversion will be at 2.5 cents per share, the same rate as the recent share placement and forthcoming rights issue. Shareholder approval will be sought at the Company's Annual General Meeting in November 2016. Accrued interest on the loan will be discharged in cash.

Optiscan Imaging Limited advises that it has revised the indicative timetable for the 2 for 9 pro rata non-renounceable Rights Issue announced on 28 June 2016.

The company is pleased to announce that it has received commitmentsfor a placement for approximately 30 million new fully paid ordinary shares at an issue price of 2.5 cents ($0.025) per share to raise approximately $750,000 before costs. Optiscan is also pleased to announce that it proposes making a non-renounceable 2 for 9 pro rata rights issue offer to shareholders. The company announces the issuance of 1,000,000 ordinary shares as consideration for a loan facility fee in respect of the existing $500,000 debt announced to the market on 29 April 2016. The shares will be issued on 1 July 2016 under the Company's existing capacity to issue shares without requiring shareholder approval.

The company lodges its 31 Dec 2015 Interim Report.

The company advises that it has arranged additional debt funding this week totalling $600,000. This includes a new facility of $500,000 secured against the 2016 R&D tax incentive claim together with a first charge over the company. A further $100,000 has been added to the existing secured facility which will now be subordinate to the new debt instrument. Together with additional revenues due shortly, the immediate solvency issue has been addressed. The Company is continuing to seek to raise capital and trading of its securities will remain in suspension until the capital raise is completed and the 31 December 2015 Half Year Interim Statements are lodged.

The Company has engaged with its secured creditor, an entity associated with Mr. Ian Mann, non-executive director and its development partner Carl Zeiss Meditec A.G. to address its immediate solvency. The Company is seeking a capital raising from sophisticated and professional investors which will be pursued during the month of April 2016. The Company will remain in suspension until it is able to confirm and make an appropriate announcement regarding the capital raising and the lodgement of its 31 December 2015 Half Year Interim Financial Statements. Based on the above further announcements are expected to be made no later than 30 April 2016.

Optiscan Imaging Limited requested a suspension of trading of its securities following the failure to complete an anticipated fund raising so as to allow the Board to evaluate options to deal with the Company's immediate solvency. Additional interim funding of $200,000 has been advanced by an entity associated with Mr. Ian Mann, non-executive director, which adds to the previous secured loan, resulting in a total secured loan outstanding of $500,000. The Company is pursuing alternative providers of R&D Loan funding to replace the previous funding mandate that was terminated.

The securities of Optiscan Imaging Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement by the Company

The securities of Optiscan Imaging Limited (the "Company") will be reinstated to quotation immediately, following the release of an announcement by the Company. Security Code: OIL

Optiscan is pleased to announce the outcome of a review of the agreement with Carl Zeiss Meditec (CZM). The collaboration is now well advanced and focused on addressing such issues as regulatory clearance and design improvements. The detail in these issues has been the subject of extensive discussions over recent months and several important positions have now been agreed upon.

The securities of Optiscan Imaging Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement by the Company. Security Code: OIL

The securities of Optiscan Imaging Limited (the "Company") will be reinstated to quotation immediately, following the release of an announcement by the Company. Security Code: OIL

The company issues a notice under S708A regarding the announced pro-rata rights issue

The company releases a new issue announcement, an application for quotation of additional securities and agreement.

The company releases an offer booklet for 15 non-renounceable pro rata entitlement offer of new shares at an issue price of $0.05 per new share. The Entitlement Offer closes at 5.00pm (Melbourne time) on Monday 6 July 2015 and is fully underwritten by Life Sciences Pty Ltd.

Optiscan is pleased to announce a $1.19m funding round. The funding will consist of $500,000 in debt and a fully underwritten 1:15 non-renounceable rights issue raising approximately $690,074.

The securities of Optiscan Imaging Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement by the Company in relation to proposed fundraising activities. Security Code: OIL

listed entity carried for record purposes only